| The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, ... Annals of oncology 26 (2), 259-271, 2015 | 2647 | 2015 |
| Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ... New England Journal of Medicine 379 (2), 111-121, 2018 | 2023 | 2018 |
| Prospective validation of a 21-gene expression assay in breast cancer JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ... New England Journal of Medicine 373 (21), 2005-2014, 2015 | 1503 | 2015 |
| Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 S Adams, RJ Gray, S Demaria, L Goldstein, EA Perez, LN Shulman, ... Journal of clinical oncology 32 (27), 2959, 2014 | 1364 | 2014 |
| Weekly paclitaxel in the adjuvant treatment of breast cancer JA Sparano, M Wang, S Martino, V Jones, EA Perez, T Saphner, AC Wolff, ... New England Journal of Medicine 358 (16), 1663-1671, 2008 | 1167 | 2008 |
| Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials B Asselain, W Barlow, J Bartlett, J Bergh, E Bergsten-Nordström, J Bliss, ... The Lancet Oncology 19 (1), 27-39, 2018 | 897 | 2018 |
| Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system CA Hudis, WE Barlow, JP Costantino, RJ Gray, KI Pritchard, ... Journal of Clinical Oncology 25 (15), 2127-2132, 2007 | 810 | 2007 |
| Case fatality rate of cancer patients with COVID-19 in a New York hospital system V Mehta, S Goel, R Kabarriti, D Cole, M Goldfinger, A Acuna-Villaorduna, ... Cancer discovery 10 (7), 935-941, 2020 | 788 | 2020 |
| Development of the 21-gene assay and its application in clinical practice and clinical trials JA Sparano, S Paik Journal of Clinical Oncology 26 (5), 721-728, 2008 | 694 | 2008 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (6), 311-335, 2017 | 672 | 2017 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (5), 235-251, 2017 | 604 | 2017 |
| A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast LJ Solin, R Gray, FL Baehner, SM Butler, LL Hughes, C Yoshizawa, ... Journal of the National Cancer Institute 105 (10), 701-710, 2013 | 561 | 2013 |
| Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life AB Moadel, C Shah, J Wylie-Rosett, MS Harris, SR Patel, CB Hall, ... Journal of Clinical Oncology 25 (28), 4387-4395, 2007 | 519 | 2007 |
| Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS … LD Kaplan, JY Lee, RF Ambinder, JA Sparano, E Cesarman, A Chadburn, ... Blood 106 (5), 1538-1543, 2005 | 480 | 2005 |
| Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism GS Karagiannis, JM Pastoriza, Y Wang, AS Harney, D Entenberg, ... Science translational medicine 9 (397), eaan0026, 2017 | 452 | 2017 |
| Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open … SA Hurvitz, M Martin, WF Symmans, KH Jung, CS Huang, AM Thompson, ... The Lancet Oncology 19 (1), 115-126, 2018 | 445 | 2018 |
| Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer JA Sparano, RJ Gray, PM Ravdin, DF Makower, KI Pritchard, KS Albain, ... New England journal of medicine 380 (25), 2395-2405, 2019 | 431 | 2019 |
| Progress in adjuvant chemotherapy for breast cancer: an overview J Anampa, D Makower, JA Sparano BMC medicine 13, 1-13, 2015 | 410 | 2015 |
| Prognostic utility of the 21-gene assay in hormone receptor–positive operable breast cancer compared with classical clinicopathologic features LJ Goldstein, R Gray, S Badve, BH Childs, C Yoshizawa, S Rowley, ... Journal of Clinical Oncology 26 (25), 4063, 2008 | 396 | 2008 |
| Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern … JA Sparano, P Bernardo, P Stephenson, WJ Gradishar, JN Ingle, S Zucker, ... Journal of Clinical Oncology 22 (23), 4683-4690, 2004 | 328 | 2004 |
